Skip to main content

Drug Interactions between taurine and vericiguat

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

taurine vericiguat

Applies to: taurine and vericiguat

MONITOR: Theoretically, concomitant use of taurine and antihypertensive agents, vasodilators, or agents with hypotensive properties may have additive blood pressure-lowering effects. The proposed mechanism has not been established but has been suggested, primarily through studies in animal models, that taurine has a homeostatic function on vascular smooth muscle and cardiac muscle. Several mechanisms by which taurine has been proposed to promote vasodilation include effects on the nitric oxide system, endothelial function, and inhibition of the renin-angiotensin-aldosterone and sympathetic systems. A 2018 meta-analysis reviewing the effects of orally administered taurine on resting systolic blood pressure (SBP) and diastolic blood pressure (DBP) in humans showed that, in the 7 studies that met the inclusion criteria, treatment with oral taurine led to a statistically significant improvement in SBP and DBP compared with placebo. The mean reduction in blood pressure was approximately 3 mmHg for both systolic and diastolic readings, with a range of 0 to 15 mmHg and 0 to 7 mmHg for SBP and DBP, respectively. The effects of taurine supplementation may also be more significant in those who are pre-hypertensive or hypertensive compared to those with normal or moderately low blood pressure, regardless of their health status. However, clinical data are limited.

MANAGEMENT: Caution and monitoring for hypotension are recommended if oral taurine supplements are used in combination with antihypertensives, or agents with hypotensive properties. Patients should be advised to contact their physician if they experience symptoms of hypotension such as dizziness, lightheadedness, or fainting.

References (1)
  1. waldron m, patterson sd, Tallent J, Jeffries O (2018) "The effects of oral taurine on resting blood pressure in humans: a meta analysis" Curr Hypertens Rep, 20, p. 1-8

Drug and food interactions

Moderate

vericiguat food

Applies to: vericiguat

ADJUST DOSING INTERVAL: Administration of vericiguat with food reduces its pharmacokinetic variability and increases its exposure. Vericiguat is less soluble at neutral pH than at acidic pH. Administration of vericiguat with a high-fat, high-calorie meal or low-fat, high-carbohydrate meal increased time to reach peak plasma concentration (Tmax) from about 1 hour (fasted) to about 4 hours (fed) and increased vericiguat systemic exposure (AUC) by 19% and peak plasma concentration (Cmax) by 9% for the 5 mg tablet and by 44% (AUC) and 41% (Cmax) for the 10 mg tablet as compared with the fasted state. Concurrent treatment with drugs that increase gastric pH, such as proton pump inhibitors or antacids, decrease vericiguat AUC by about 30%. Co-treatment with drugs that increase gastric pH did not affect vericiguat exposure in patients with heart failure when vericiguat was taken as directed with food.

MANAGEMENT: Administer vericiguat with food to ensure maximal exposure and decrease pharmacokinetic variability.

References (2)
  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. (2021) "Product Information. Verquvo (vericiguat)." Merck & Co., Inc

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.